This map shows the geographic impact of M Slavík's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Slavík with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Slavík more than expected).
This network shows the impact of papers produced by M Slavík. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Slavík. The network helps show where M Slavík may publish in the future.
Co-authorship network of co-authors of M Slavík
This figure shows the co-authorship network connecting the top 25 collaborators of M Slavík.
A scholar is included among the top collaborators of M Slavík based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with M Slavík. M Slavík is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Hájek, Roman, Jiří Vorlíček, & M Slavík. (1996). Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.. PubMed. 43(3). 141–54.34 indexed citations
Slavík, M, et al.. (1987). Therapy for advanced renal cell cancer with spirogermanium: a Southwest Oncology Group Study.. PubMed. 71(2). 207–8.6 indexed citations
8.
Blumenstein, Brent A., et al.. (1987). Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group Study.. PubMed. 71(12). 1305–6.1 indexed citations
9.
Wagner, S A & M Slavík. (1984). An individualized plastic intraoral device for the collection of human parotid saliva.. PubMed. 22(5). 236–9.4 indexed citations
10.
Mrema, John E. K., et al.. (1983). Spirogermanium: a new drug with antimalarial activity against chloroquine-resistant Plasmodium falciparum.. PubMed. 21(4). 167–71.10 indexed citations
11.
Schein, P S, et al.. (1980). Phase I clinical trial of spirogermanium.. PubMed. 64(10-11). 1051–6.29 indexed citations
12.
Slavík, M. (1979). Changes in amino acid metabolism caused by 6-azauridine triacetate: relevance to cancer treatment.. PubMed. 63(6). 1041–4.6 indexed citations
Hoff, Daniel D. Von, John S. Penta, Lee J. Helman, & M Slavík. (1977). Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.. PubMed. 61(4). 745–8.102 indexed citations
15.
Slavík, M. (1976). Clinical studies with nitrosoureas in various solid tumors.. PubMed. 60(6). 795–800.9 indexed citations
16.
Slavík, M, et al.. (1975). Changes in preference for NaCl following administration of 6-azauridine and 6-azauridine triacetate.. PubMed. 2(1). 25–32.3 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.